Megan A. Healey, PhD, MPH
Clinical Associate Professor
Boston University School of Public Health

PhD, Johns Hopkins University School of Medicine
MPH, Harvard School of Public Health
BA, Clark University

Pronouns: she/her/hers

Megan Healey, PhD, MPH is a molecular epidemiologist with expertise in epigenetics and breast cancer. Dr. Healey uses population-based studies to investigate molecular determinants of cancer subtypes and prognosis. Trained as a bench scientist, Dr. Healey completed research fellowships in cancer epigenetics at Johns Hopkins and cancer epidemiology at Harvard. She transitioned from biomedical science to public health in hopes of leveraging her interdisciplinary background to improve the health of populations. Part of that mission is to help train our future leaders in public health. Dr. Healey is invested in bringing innovative, integrated and practical approaches to learning in the classroom, particularly in large courses. Currently, Dr. Healey teaches Quantitative Methods for Public Health, Concepts and Methods in Epidemiology, and Cancer Epidemiology. She is the recipient of the BUSPH Educational Innovation Award and several BUSPH Excellence in Teaching Awards. Dr. Healey is the Director of MPH Programs.

Diversity, Equity, Inclusion and Accessibility

Diversity, equity, inclusion, and access (DEIA) are foundational to creating a culture of belonging and a more fair, healthy, and just world. My DEIA work spans the classroom, the Department of Epidemiology, and BUSPH.

To make our quantitative courses more accessible and more inclusive for our students, Prof. Jacqui Hicks and I received a BUSPH educational grant to implement a Quantitative Curriculum Fellowship Program. We are working with current students at SPH and Wheelock College of Education and Human Development to identify and incorporate diverse scholarship and perspectives, representative datasets and examples, and create digital resources to better support our first-generation students and students with more limited programming and math backgrounds.

As a member of the Epidemiology Department's Antiracism Committee, I am working with my colleagues to bring forward several initiatives, including an ongoing seminar series on racism and health, and an emerging scholars program for early career BIPOC scholars.

As a member of the school-wide DEIJ Committee, I worked on an education subcommittee to develop a new DEIA syllabus assessment tool. The goal is to jumpstart conversations and considerations for creating an inclusive classroom and learning experience for our future public health leaders and practitioners.

Detecting Breast Cancer with a Simple Blood Test Using an Accessible and Low-Cost Novel Real-Time Platform
12/01/2021 - 12/31/2022 (PI)
Inanovate, Inc.


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Werler MM, Stuver SO, Healey MA, LaMorte WW. The Future of Teaching Epidemiology. Am J Epidemiol. 2019 05 01; 188(5):825-829.View Related Profiles. PMID: 30865216
  2. Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, Holmes MD, Tamimi RM, Hazra A. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. Breast Cancer Res Treat. 2017 Nov; 166(2):613-622. PMID: 28791482; PMCID: PMC6995281; DOI: 10.1007/s10549-017-4421-3;
  3. Healy MA. A "microounce" of cancer prevention. Public Health Post. 2017.
  4. Healey MA, Hu R, Beck AH, Collins LC, Schnitt SJ, Tamimi RM, Hazra A. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. Breast Cancer Res Treat. 2014 Oct; 147(3):639-51. PMID: 25224916; DOI: 10.1007/s10549-014-3089-1;
  5. Hossain MZ, Healey MA, Lee C, Poh W, Yerram SR, Patel K, Azad NS, Herman JG, Kern SE. DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells. Oncotarget. 2013 Feb; 4(2):298-309. PMID: 23593653; PMCID: PMC3712575; DOI: 10.18632/oncotarget.863;
  6. Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC. The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research. Cancer Prev Res (Phila). 2011 Apr; 4(4):616-21.View Related Profiles. PMID: 21464034; PMCID: PMC4827425; DOI: 10.1158/1940-6207.CAPR-11-0018;
  7. Healey MA, Deaton SL, Alder JK, Winnepenninckx V, Casero RA, Herman JG. Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma. Epigenetics. 2010 Jul 1; 5(5):410-21. PMID: 20484992; PMCID: PMC3654680; DOI: 10.4161/epi.5.5.11929;
  8. Cummings SD, Ryu B, Samuels MA, Yu X, Meeker AK, Healey MA, Alani RM. Id1 delays senescence of primary human melanocytes. Mol Carcinog. 2008 Sep; 47(9):653-9.View Related Profiles. PMID: 18240291; PMCID: PMC4066980; DOI: 10.1002/mc.20422;
  9. Ryu B, Kim DS, DeLuca AM, Healey MA, Dunlap S, Fackler MJ, Herman J, Alani RM. Id1 expression is transcriptionally regulated in radial growth phase melanomas. Int J Cancer. 2007 Oct 15; 121(8):1705-9.View Related Profiles. PMID: 17565736
  10. Esni F, Ghosh B, Biankin AV, Lin JW, Albert MA, Yu X, MacDonald RJ, Civin CI, Real FX, Pack MA, Ball DW, Leach SD. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development. 2004; 131(17):4213-24.
Showing 10 of 11 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 11 publications over 10 distinct years, with a maximum of 2 publications in 2017

Contact for Mentoring:

715 Albany St Talbot Building
Boston MA 02118
Google Map

Healey's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department